Insider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Buys 10,000 Shares of Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock in a transaction on Tuesday, February 25th. The shares were acquired at an average cost of $4.46 per share, for a total transaction of $44,600.00. Following the completion of the transaction, the chief executive officer now owns 2,331,730 shares of the company’s stock, valued at $10,399,515.80. This represents a 0.43 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Vanda Pharmaceuticals Trading Up 2.5 %

Shares of NASDAQ VNDA opened at $4.46 on Wednesday. The firm has a 50-day moving average of $4.59 and a two-hundred day moving average of $4.81. The company has a market capitalization of $260.09 million, a price-to-earnings ratio of -13.94 and a beta of 0.74. Vanda Pharmaceuticals Inc. has a twelve month low of $3.71 and a twelve month high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. The business had revenue of $53.19 million for the quarter, compared to the consensus estimate of $51.00 million. As a group, research analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

VNDA has been the subject of a number of research analyst reports. StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a “hold” rating for the company. HC Wainwright boosted their target price on shares of Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th.

Institutional Investors Weigh In On Vanda Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets grew its stake in Vanda Pharmaceuticals by 1,184.6% in the third quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company’s stock valued at $292,000 after acquiring an additional 57,393 shares during the period. FMR LLC raised its stake in Vanda Pharmaceuticals by 25.9% in the 3rd quarter. FMR LLC now owns 149,739 shares of the biopharmaceutical company’s stock valued at $702,000 after acquiring an additional 30,802 shares during the period. Massachusetts Financial Services Co. MA bought a new stake in Vanda Pharmaceuticals in the 3rd quarter valued at $864,000. GSA Capital Partners LLP acquired a new position in Vanda Pharmaceuticals in the 3rd quarter valued at $143,000. Finally, Barclays PLC grew its holdings in Vanda Pharmaceuticals by 128.2% in the 3rd quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company’s stock valued at $722,000 after buying an additional 86,677 shares in the last quarter. 88.14% of the stock is owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.